Evolocumab在家族性高胆固醇血症患者中的长期应用
这项开放标签单臂研究纳入300例HoFH或重度HeFH患者,评估Evolocumab长期安全性和疗效。中位随访4.1年,不良反应发生率89.3%,HoFH和重度HeFH的LDL-C分别降低21.2%和54.9%,心血管事件年发生率为2.7%。
要点
- Evolocumab在HoFH和重度HeFH患者中耐受性良好,LDL-C降低持续存在。
- HoFH患者LDL-C降低21.2%,重度HeFH降低54.9%,上调剂量可进一步改善。
- adjudicated心血管事件年发生率为2.7%,部分患者停止脂蛋白血浆置换。
核心结论
- Evolocumab在HoFH和重度HeFH患者中耐受良好,并能有效降低LDL-C水平,中位随访4.1年。
研究设计与样本
- 开放标签、单臂研究,纳入300例HoFH或重度HeFH患者(其中HoFH 106例,包括14例<18岁),接受皮下Evolocumab 420 mg每月一次或每两周一次(血浆置换者),12周后非血浆置换者可上调至每两周一次。
主要发现
- 不良反应发生率89.3%,最常见为上呼吸道感染、流感、鼻咽炎和头痛。
- HoFH患者从基线至第12周LDL-C平均变化为-21.2%(-59.8 mg/dl),重度HeFH为-54.9%(-104.4 mg/dl),并随时间维持。
- 48例HoFH患者上调剂量后,LDL-C平均变化从第12周的-19.6%改善至每两周420 mg治疗12周后的-29.7%。
- adjudicated心血管事件年发生率为2.7%。
- 61例入组时接受血浆置换的患者中,16例停止血浆置换。
临床怎么用
- 对于HoFH或重度HeFH且无法达到LDL-C目标的患者,可考虑使用Evolocumab长期治疗以降低LDL-C。
局限性
- 研究为单臂开放标签设计,缺乏对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 inhibitor therapy is a treatment option for patients with familial hypercholesterolemia (FH) who are unable to reach low-density lipoprotein cholesterol (LDL-C) goals. OBJECTIVES: The aim of this study was to provide long-term safety and efficacy data for evolocumab in patients with homozygous FH (HoFH) and severe heterozygous FH (HeFH). METHODS: In this open-label, single-arm study, patients with HoFH or severe HeFH ≥12 years of age and on stable lipid-lowering therapy began subcutaneous evolocumab 420 mg monthly or 420 mg every 2 weeks if on lipoprotein apheresis. After 12 weeks, those not on apheresis could be up-titrated to 420 mg every 2 weeks. The primary endpoint was the incidence of treatment-emergent adverse events; secondary endpoints were changes in LDL-C and other lipids. RESULTS: In total, 300 patients (106 with HoFH, including 14 <18 years of age at enrollment) received evolocumab for a median of 4.1 years. Adverse events occurred in 89.3% of patients, the most common of which were nasopharyngitis, influenza, upper respiratory tract infection, and headache. Mean change in LDL-C from baseline to week 12 was -21.2% (-59.8 mg/dl) in patients with HoFH and -54.9% (-104.4 mg/dl) in those with severe HeFH and was sustained over time. Of 48 patients with HoFH who were up-titrated, mean change in LDL-C improved from -19.6% at week 12 to -29.7% after 12 weeks of 420 mg every 2 weeks. The adjudicated cardiovascular event rate was 2.7% per year. Of 61 patients receiving apheresis at enrollment, 16 discontinued apheresis. CONCLUSIONS: Evolocumab was well tolerated and effectively reduced plasma LDL-C levels in patients with HoFH and severe HeFH over a median of 4.1 years.
引用
- Santos RD, Stein EA, Hovingh GK, et al. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. J Am Coll Cardiol. 2020. PMID: 32057369. doi:10.1016/j.jacc.2019.12.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。